Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
46.4M
-
Shares change
-
+873K
-
Total reported value, excl. options
-
$568M
-
Value change
-
+$9.03M
-
Put/Call ratio
-
1.25
-
Number of buys
-
62
-
Number of sells
-
-57
-
Price
-
$12.23
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q1 2020
168 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2020.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.4M shares
of 108M outstanding shares and own 43.08% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (10.2M shares), Sumitomo Mitsui Trust Holdings, Inc. (7.09M shares), Nikko Asset Management Americas, Inc. (7.09M shares), BlackRock Inc. (3.79M shares), VANGUARD GROUP INC (3.49M shares), STATE STREET CORP (1.72M shares), Atlas Venture Associates IX, LLC (1.62M shares), Chevy Chase Trust Holdings, Inc. (1.38M shares), DIMENSIONAL FUND ADVISORS LP (1.02M shares), and CITADEL ADVISORS LLC (897K shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.